Keyphrases
Non-small Cell Lung Cancer (NSCLC)
90%
Epidermal Growth Factor Receptor
65%
Anaplastic Lymphoma Kinase Rearrangement
65%
Crizotinib
56%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
47%
Resistance Mechanisms
47%
Acquired Resistance
45%
Lung Adenocarcinoma
45%
Epithelial-mesenchymal Transition
43%
Anaplastic Lymphoma Kinase
43%
EGFR mutation
43%
Non-small Cell Lung Cancer Patients
42%
Adenocarcinoma
28%
EGFR-TKI Resistance
28%
Anaplastic Lymphoma Kinase Fusion
27%
Denmark
26%
Alectinib
25%
Working Diagnosis
25%
Re-biopsy
25%
EML4
23%
Intrinsic Resistance
23%
ALK-positive Lung Cancer
23%
Anaplastic Lymphoma Kinase-positive
21%
ALK Tyrosine Kinase Inhibitors
21%
Uncommon Presentation
21%
Acquired T790M
21%
Heterogeneous Resistance
21%
ALK-positive NSCLC
21%
V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog
21%
Retrospective Cohort Study
21%
Lung Cancer Patients
21%
Fibroblast Growth Factor Receptor 3 (FGFR3)
21%
Erlotinib
21%
Clinical Outcomes
21%
Carcinoid
21%
Thoracic Lesion
21%
Labor Market
21%
Small Cell Lung Cancer
21%
Exon 19
21%
Primary Lung Cancer
21%
Rare Case Report
21%
BRAF mutation
21%
Granulomatosis with Polyangiitis
21%
Atypical Carcinoid
21%
Metastatic Lung Cancer
21%
Median Overall Survival
18%
Tyrosine Kinase Inhibitor Resistance
18%
ALK Inhibitor
17%
Crizotinib Resistance
16%
Co-mutation
15%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Anaplastic Lymphoma Kinase
86%
Epidermal Growth Factor Receptor
86%
Protein Tyrosine Kinase Inhibitor
67%
Crizotinib
55%
Overall Survival
44%
Disease
30%
Lung Adenocarcinoma
25%
Lung Cancer
23%
Intrinsic Resistance
23%
Epidermal Growth Factor Receptor Kinase Inhibitor
23%
Erlotinib
21%
Prevalence
21%
Small Cell Lung Cancer
21%
Fibroblast Growth Factor Receptor 3
21%
Sarcoma
21%
Retrospective Study
10%
Adenocarcinoma
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
65%
Epidermal Growth Factor Receptor
43%
Lung Cancer
43%
Anaplastic Lymphoma Kinase
43%
Tyrosine-Kinase Inhibitor
38%
Adenocarcinoma
23%
Fibroblast Growth Factor Receptor 3
21%
Exon
21%
Granulomatosis with Polyangiitis
21%
Small Cell Lung Cancer
21%
Erlotinib
21%
Mesenchymal-Epithelial Transition
21%
Carcinoid
21%
Pleura Effusion
9%
Mediastinal Lymph Node
9%
Neoplasm
7%
Differential Diagnosis
7%
Granulomatous Inflammation
7%
Final Diagnosis
7%
Systemic Vasculitis
7%
Cervical Lymph Node
7%
Biopsy
7%
Renal Biopsy
7%
Lung Adenocarcinoma
6%
Mixed Tumor
5%